Cardiovascular Trials Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Cardiovascular Research Group, Core Technologies Facility, University of Manchester, Manchester, UK.
Cardiovascular Trials Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Barlow Medical Centre, Manchester, UK.
Atherosclerosis. 2016 Sep;252:161-165. doi: 10.1016/j.atherosclerosis.2016.07.009. Epub 2016 Jul 10.
Untreated individuals with familial hypercholesterolaemia (FH) are at increased risk of developing premature cardiovascular disease (CVD). Early diagnosis and treatment can result in a normal life expectancy. A recent survey commissioned by the European Atherosclerosis Society (EAS) reported a lack of awareness of FH in the general population. We conducted a survey to assess knowledge among healthcare professionals involved in the assessment and management of cardiovascular risk and disease in the United Kingdom.
A survey designed to assess knowledge of diagnostic criteria, risk assessment, the role of cascade screening, and management options for patients with FH was distributed to 1000 healthcare professionals (response rate 44.3%). The same survey was redistributed following attendance at an educational session on FH.
151 respondents (40.5%) reported having patients under their care who would meet the diagnostic criteria for FH, but just 61.4% recognized that cardiovascular risk estimation tools cannot be applied in FH, and only 22.3% understood the relative risk of premature CVD compared to the general population. Similarly, just 65.9% were aware of recommendations regarding cascade screening.
The prevalence and associated risk of FH continue to be underestimated, and knowledge of diagnostic criteria and treatment options is suboptimal. These results support the recent Consensus Statement of the EAS and production of quality standards by the National Institute for Health and Care Excellence. Further work is required to formulate interventions to improve FH awareness and knowledge, and to determine the effect these interventions have on patient outcomes.
未经治疗的家族性高胆固醇血症(FH)患者发生早发性心血管疾病(CVD)的风险增加。早期诊断和治疗可以使预期寿命恢复正常。最近,欧洲动脉粥样硬化学会(EAS)委托进行的一项调查显示,普通人群对 FH 的认识不足。我们进行了一项调查,以评估参与评估和管理英国心血管风险和疾病的医疗保健专业人员的知识。
一项旨在评估 FH 患者诊断标准、风险评估、级联筛查作用以及管理选择知识的调查,分发给 1000 名医疗保健专业人员(回应率 44.3%)。在 FH 教育会议后,重新分发了相同的调查。
151 名受访者(40.5%)报告称,他们负责的患者符合 FH 的诊断标准,但只有 61.4%认识到心血管风险评估工具不能用于 FH,只有 22.3%了解与普通人群相比,早发性 CVD 的相对风险。同样,只有 65.9%的人了解级联筛查的建议。
FH 的患病率和相关风险继续被低估,并且对诊断标准和治疗选择的认识不足。这些结果支持 EAS 的最新共识声明以及国家卫生与保健卓越研究所制定的质量标准。需要进一步努力制定干预措施,以提高 FH 的认识和知识,并确定这些干预措施对患者结果的影响。